FibroBiologics, Inc.
$1.53
▲
3.76%
2026-04-21 06:47:01
fibrobiologics.com
NCM: FBLG
Explore FibroBiologics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.37 M
Current Price
$1.53
52W High / Low
$30.6 / $1.03
Stock P/E
—
Book Value
$1.85
Dividend Yield
—
ROCE
-211.82%
ROE
-4.19%
Face Value
—
EPS
$-8.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
1.1
Debt / Equity
39.15
Current Ratio
3.61
Quick Ratio
3.61
Forward P/E
-0.25
Price / Sales
—
Enterprise Value
$2.08 M
EV / EBITDA
-0.13
EV / Revenue
—
Rating
Buy
Target Price
$43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 2. | Verrica Pharmaceuticals Inc. | $6.38 | — | $109.6 M | — | -38.9% | -2.4% | $9.82 / $3.28 | $1.44 |
| 3. | HCW Biologics Inc. | $0.41 | — | $2.94 M | — | -4764.31% | -897.37% | $17.8 / $0.25 | $-0.8 |
| 4. | Instil Bio, Inc. | $8.39 | — | $56.9 M | — | -26.15% | -50.39% | $42.79 / $5.67 | $16.79 |
| 5. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
| 6. | Kymera Therapeutics, Inc. | $88.84 | — | $7.31 B | — | -20.82% | -25.78% | $103 / $24.43 | $19.42 |
| 7. | Kodiak Sciences Inc. | $46.44 | — | $2.87 B | — | -76.6% | -1.49% | $47.41 / $2.34 | $2.55 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.59 M | -5.04 M | -4.49 M | -4.53 M | -3.71 M | — |
| Net Profit | -3.24 M | -5.78 M | -4.66 M | -4.97 M | -3.1 M | — |
| EPS in Rs | -0.71 | -1.27 | -1.03 | -1.09 | -0.68 | -0.01 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -16.65 M | -13.74 M | -8.89 M | -4.47 M |
| Net Profit | -18.65 M | -11.16 M | -16.48 M | -5.12 M |
| EPS in Rs | -4.11 | -2.46 | -3.63 | -1.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.62 M | 16.45 M | 11.82 M | 4.82 M |
| Total Liabilities | 3.46 M | 13.71 M | 10.57 M | 8.82 M |
| Equity | 6.16 M | 2.73 M | 1.25 M | -4 M |
| Current Assets | 6.35 M | 14.23 M | 9.21 M | 2.62 M |
| Current Liabilities | 1.76 M | 12.73 M | 9.18 M | 7.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -16.39 M | -11.9 M | -6.4 M | -4.07 M |
| Investing CF | -0.26 M | -0.18 M | -0.49 M | 0 M |
| Financing CF | 7.57 M | 16.91 M | 13.79 M | 5.92 M |
| Free CF | -16.66 M | -12.09 M | -6.9 M | -4.07 M |
| Capex | -0.26 M | -0.18 M | -0.49 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -67.06% | 32.3% | -221.91% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-30 | 1:0.05 |